The TAXUS Element Stent System is currently being studied in the PERSEUS clinical trial program, which compares the TAXUS Element Stent System to the TAXUS(R) Express(2)(R) Stent System. The program includes the PERSEUS Workhorse and the PERSEUS Small Vessel arms. Both have finished recruiting patients and are estimated to be completed by the end of the year.
While the Element Stent platform represents Boston Scientific's third-generation DES technology, the Company's fourth-generation DES is currently under development. Initial clinical data were presented at the Transcatheter Cardiovascular Therapeutics scientific symposium in 2008; global pivotal trials are expected to begin in 2010. This DES employs the Labcoat technology, which has an ultra thin biodegradable abluminal polymer that delivers a very low dose of paclitaxel to the wall of the treated vessel, and no polymer or drug on the inner surface of the stent. Integrating the Element Stent architecture and a platinum chromium alloy with an optimized drug release, the "Labcoat Element" Stent is designed to deliver a powerful combination of procedural and clinical performance.
In the United States, the TAXUS Element Stent is an investigational device and is limited by applicable law to investigational use only and is not available for sale.
Forward Looking Statements --------------------------
Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimates," "continues," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the m
|SOURCE Angiotech Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved